- US-listed companies
- Akari Therapeutics Plc
- Income statement
Akari Therapeutics Plc (AKTX) Income statement
Market cap
$531.1B
P/E ratio
| 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Research & development | 7 | 6 | 6 | 17 | 23 | 12 | 9 | 9 | 9 | 10 | 5 | - | 3 |
| Selling, general & administrative | 10 | 4 | 6 | 10 | 12 | 11 | 8 | 9 | 8 | 14 | 11 | - | 9 |
| Operating expenses | - | - | 31 | 27 | 38 | 20 | 17 | 18 | 17 | 23 | - | - | 17 |
| Operating income | -4 | -10 | -30,584,570 | -27,246,558 | -37,784,189 | -19,991,534 | -16,963,120 | -17,980,974 | -17,214,136 | -23,088,208 | -17 | - | -17 |
| Income before tax | - | - | -45,317,532 | - | - | - | - | - | - | - | - | - | -18 |
| Provision for income taxes | - | - | - | - | - | - | - | - | - | - | - | - | -1 |
| Effective tax rate (%) | - | - | - | - | - | - | - | - | - | - | - | - | |
| Net income | -4 | -10 | -45,317,532 | -18,140,997 | -35,399,257 | -16,466,780 | -17,105,791 | -17,081,617 | -17,424,237 | -17,748,062 | -10 | -20 | -17 |
| Earnings per share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - |